HRT Financial’s Quest Diagnostics DGX Stock Holding History

HRT Financial’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-6,782	Closed	-$1.15M	–	2802
2025 Q1	$1.15M	Buy	+6,782	New	+$1.11M	0.01%	1063
2024 Q3	–	Sell	-26,148	Closed	-$3.58M	–	2564
2024 Q2	$3.58M	Buy	+26,148	New	+$3.58M	0.02%	506
2023 Q3	–	Sell	-21,031	Closed	-$2.96M	–	2537
2023 Q2	$2.96M	Buy	+21,031	New	+$2.9M	0.03%	458
2023 Q1	–	Sell	-32,254	Closed	-$5.04M	–	2617
2022 Q4	$5.04M	Buy	+32,254	New	+$4.63M	0.07%	265
2021 Q4	–	Sell	-187,104	Closed	-$27.2M	–	3344
2021 Q3	$27.2M	Buy	187,104 +167,228	+841%	+$24.5M	0.17%	62
2021 Q2	$2.62M	Buy	+19,876	New	+$2.6M	0.02%	508
2021 Q1	–	Sell	-19,457	Closed	-$2.32M	–	2772
2020 Q4	$2.32M	Buy	+19,457	New	+$2.37M	0.05%	294
2020 Q3	–	Sell	-9,052	Closed	-$1.03M	–	1983
2020 Q2	$1.03M	Buy	+9,052	New	+$960K	0.03%	539
2018 Q1	–	Sell	-9,919	Closed	-$976K	–	211
2017 Q4	$976K	Buy	+9,919	New	+$940K	0.99%	16

Other funds holding DGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

HRT Financial's DGX Position: Q2 2025 in Review

HRT Financial sold out of Quest Diagnostics (DGX) in Q2 2025, closing a stake of 6,782 shares — an estimated $1.15M sold.

HRT Financial first reported a position in DGX in Q4 2017 and held it in 9 quarters. The position peaked at $27.2M in Q3 2021. 990 funds tracked by Wall St. Rank hold DGX as of Q2 2025.

HRT Financial reported no remaining Quest Diagnostics position as of Q2 2025 after selling out during the quarter.
HRT Financial sold 6,782 Quest Diagnostics shares in Q2 2025, an estimated $1.15M.
HRT Financial first reported a position in Quest Diagnostics in Q4 2017 and held it in 9 quarters.
HRT Financial's Quest Diagnostics position peaked at $27.2M in Q3 2021.
990 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2025.

Based on HRT Financial's 13F filing for Q2 2025, filed 14 Aug 2025.